A Risk Assessment and Risk-Based Approach Review of Pre-Use/Post-Sterilization Integrity Testing (PUPSIT).

Kelly Waldron, Amanda McFarland, Hal Baseman, Maik Jornitz
{"title":"A Risk Assessment and Risk-Based Approach Review of Pre-Use/Post-Sterilization Integrity Testing (PUPSIT).","authors":"Kelly Waldron, Amanda McFarland, Hal Baseman, Maik Jornitz","doi":"10.5731/pdajpst.2024-003038.1","DOIUrl":null,"url":null,"abstract":"<p><p>In January 2023, ICH Q9 was updated to include expanded guidance on risk-based decision-making, emphasizing its application in informing science-driven and strategic decisions. The revised guidance highlights that while quality risk management can aid decision-making, it does not eliminate the industry's obligation to comply with regulatory requirements. This article introduces a framework for evaluating the risks and benefits of pre-use/post-sterilization integrity testing (PUPSIT) using risk management principles. It provides a structured approach to assess the acceptability of alternative methods to the EU Annex 1 PUPSIT requirement, which acknowledges that PUPSIT may not always be feasible due to constraints such as the filtration of small solution volumes. In such cases, Annex 1 permits alternative approaches if a comprehensive risk assessment is conducted and effective controls are implemented to mitigate the risk of non-integral filtration systems. The proposed framework considers three critical domains-patient safety, process integrity, and regulatory compliance-to ensure decisions are well-informed and balanced. By applying this science- and risk-based approach, organizations can navigate PUPSIT requirements effectively, ensuring compliance while addressing operational limitations.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":"79 1","pages":"88-97"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2024-003038.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In January 2023, ICH Q9 was updated to include expanded guidance on risk-based decision-making, emphasizing its application in informing science-driven and strategic decisions. The revised guidance highlights that while quality risk management can aid decision-making, it does not eliminate the industry's obligation to comply with regulatory requirements. This article introduces a framework for evaluating the risks and benefits of pre-use/post-sterilization integrity testing (PUPSIT) using risk management principles. It provides a structured approach to assess the acceptability of alternative methods to the EU Annex 1 PUPSIT requirement, which acknowledges that PUPSIT may not always be feasible due to constraints such as the filtration of small solution volumes. In such cases, Annex 1 permits alternative approaches if a comprehensive risk assessment is conducted and effective controls are implemented to mitigate the risk of non-integral filtration systems. The proposed framework considers three critical domains-patient safety, process integrity, and regulatory compliance-to ensure decisions are well-informed and balanced. By applying this science- and risk-based approach, organizations can navigate PUPSIT requirements effectively, ensuring compliance while addressing operational limitations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用前/灭菌后完整性检测(PUPSIT)的风险评估和基于风险的方法综述。
2023年1月,ICH Q9进行了更新,扩大了对基于风险的决策的指导,强调其在为科学驱动的战略决策提供信息方面的应用。修订后的指南强调,虽然质量风险管理可以帮助决策,但它并没有消除行业遵守监管要求的义务。本文介绍了一个使用风险管理原则评估使用前/灭菌后完整性测试(PUPSIT)的风险和收益的框架。它提供了一种结构化的方法来评估欧盟附件1 PUPSIT要求的替代方法的可接受性,其中承认由于过滤小溶液体积等限制,PUPSIT可能并不总是可行的。在这种情况下,如果进行了全面的风险评估并实施了有效的控制以减轻非整体过滤系统的风险,则附录1允许采用替代方法。拟议的框架考虑了三个关键领域——患者安全、流程完整性和法规遵从性——以确保决策是充分知情和平衡的。通过应用这种基于科学和风险的方法,组织可以有效地驾驭PUPSIT需求,在解决操作限制的同时确保遵从性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
期刊最新文献
Development, Validation, and Implementation of a Pharmaceutical Facility Disinfection Program. Evaluation of the Effect of Single-Temperature Incubation on the Recovery and Behavior of Microbiota in the Context of Environmental Monitoring. Global health authorities review and approval trends for CMC post approval changes 2018-2024. Gamma Irradiation of Ready-to-Use Injectable Aqueous Suspensions: Impact on Particle Size, Rheology, Interfacial Properties, and Polymer Stability. Root Cause Determination for Customer Complaint Biopharmaceutical Drug Product Samples with Abnormal Appearance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1